课题基金 / 基金详情

ARRA ^ Preclinical Studies of Vaccines for Pandemic H1N1 Influenza

ARRA ^ Preclinical Studies of Vaccines for Pandemic H1N1 Influenza
ARRA ^ 大流行性 H1N1 流感疫苗的临床前研究
批准号：
7964771
负责人：
Kanta Subbarao
金额：
$4.59万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/7964771
关键词：
Animal ModelAnimalsAntibody FormationAttenuatedAttenuated Live Virus VaccineBase SequenceBiological AssayBirdsCenters for Disease Control and Prevention (U.S.)Clinical TrialsCooperative Research and Development AgreementDiseaseDoseEpidemicEquilibriumEvaluationEventExhibitsFamily suidaeFormalinGenesGoalsHemagglutinationHemagglutininHumanHuman Influenza A VirusImmune responseInfectionInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A virusLicensureLifeMembrane GlycoproteinsMutationNeedlesNeuraminidasePhenotypePlasmidsPopulationProteinsReportingSafetyScientistSerumSpecific qualifier valueTemperatureUnited StatesVaccinatedVaccinesVirusWorld Health Organizationaquatic birdattenuationbaseimmunogenicityinfluenza virus vaccineinfluenzavirusneutralizing antibodynovelpandemic diseasepandemic influenzapositional cloningpreclinical studyprogramsvaccine candidatevaccine developmentvaccine efficacy

项目摘要

项目成果

Kanta Subbarao的其他基金

相似基金

相关文献

中文摘要
翻译
LID的科学家正在CRADA的框架下与医学免疫的科学家合作，以生产针对大流行性流感病毒的候选疫苗，包括2009年大流行的H1N1病毒。该疫苗是用基于质粒的反向遗传学产生的，包含来自大流行的h1n1流感病毒的血凝素和神经氨酸酶基因，以及来自aa ca病毒的六个内部基因片段。疫苗的免疫原性和效力将在动物模型中进行评估。将使用血凝抑制和中和抗体分析来评估一剂或两剂疫苗的血清抗体反应，并将通过用野生型H1N1大流行流感病毒攻击接种疫苗的动物来评估其效果。
英文摘要
LID scientists are collaborating with scientists from MedImmune under a CRADA to generate candidate vaccines against pandemic influenza viruses, including the 2009 pandemic H1N1 virus. The vaccine was generated using plasmid based reverse genetics and contains the hemagglutinin and neuraminidase genes from the pandemic H1N1 influenza virus and six internal gene segments from the AA ca virus. The immunogenicity and efficacy of the vaccine will be evaluated in animal models. The serum antibody response to one or two doses of vaccine will be evaluated using hemagglutination inhibition and neutralizing antibody assays and the efficacy will be evaluated by challenging vaccinated animals with the wild-type H1N1 pandemic influenza virus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EVAL. OF VACCINE AGAINST HIGHLY PATHOGENIC INFLUENZA A(H5N1) VIRUS IN MACAQUES
Vaccines for Pandemic Influenza
Preclinical Studies of Vaccines for Pandemic Influenza
Clinical Studies of Vaccines for Pandemic Influenza
海外基金